DE602005022939D1 - Zusammensetzungen zur bekämpfung von beta-lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen - Google Patents

Zusammensetzungen zur bekämpfung von beta-lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen

Info

Publication number
DE602005022939D1
DE602005022939D1 DE602005022939T DE602005022939T DE602005022939D1 DE 602005022939 D1 DE602005022939 D1 DE 602005022939D1 DE 602005022939 T DE602005022939 T DE 602005022939T DE 602005022939 T DE602005022939 T DE 602005022939T DE 602005022939 D1 DE602005022939 D1 DE 602005022939D1
Authority
DE
Germany
Prior art keywords
beta
compositions
lactamase
normally
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005022939T
Other languages
German (de)
English (en)
Inventor
Manu Chaudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Venus Remedies Ltd
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of DE602005022939D1 publication Critical patent/DE602005022939D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DE602005022939T 2004-12-02 2005-11-28 Zusammensetzungen zur bekämpfung von beta-lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen Expired - Lifetime DE602005022939D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2411DE2004 2004-12-02
PCT/IN2005/000382 WO2006059344A1 (en) 2004-12-02 2005-11-28 Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection

Publications (1)

Publication Number Publication Date
DE602005022939D1 true DE602005022939D1 (de) 2010-09-23

Family

ID=35789266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022939T Expired - Lifetime DE602005022939D1 (de) 2004-12-02 2005-11-28 Zusammensetzungen zur bekämpfung von beta-lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen

Country Status (23)

Country Link
US (2) US8273732B2 (https=)
EP (1) EP1841432B1 (https=)
JP (1) JP5269415B2 (https=)
KR (2) KR101244362B1 (https=)
CN (1) CN101060846A (https=)
AT (1) ATE476981T1 (https=)
AU (1) AU2005310888B2 (https=)
BR (1) BRPI0517128A (https=)
CY (1) CY1110886T1 (https=)
DE (1) DE602005022939D1 (https=)
DK (1) DK1841432T3 (https=)
ES (1) ES2349301T3 (https=)
HR (1) HRP20100591T1 (https=)
MX (1) MX2007006540A (https=)
NZ (1) NZ555075A (https=)
PL (1) PL1841432T3 (https=)
PT (1) PT1841432E (https=)
RS (1) RS51506B (https=)
RU (1) RU2397768C2 (https=)
SI (1) SI1841432T1 (https=)
UA (1) UA91204C2 (https=)
WO (1) WO2006059344A1 (https=)
ZA (1) ZA200704394B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030010176A (ko) * 2001-07-25 2003-02-05 이병두 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
WO2010013640A1 (ja) * 2008-07-28 2010-02-04 Yamaguchi Keizo 感染症治療効果増強剤
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
PT2714034T (pt) * 2011-05-28 2018-10-30 Wockhardt Ltd Composições que compreendem cefepime e tazobactam
EP2768503A1 (en) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
KR101536885B1 (ko) 2012-03-26 2015-07-14 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
RU2671485C2 (ru) * 2012-09-27 2018-11-01 Мерк Шарп И Доум Корп. Антибиотические композиции тазобактама аргинина
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
KR20160130824A (ko) * 2014-03-29 2016-11-14 욱크하르트 리미티드 세페파임 또는 술박탐을 포함하는 제약학적 조성물
WO2015151264A1 (ja) * 2014-04-03 2015-10-08 キユーピー株式会社 注射液用袋及び注射用製剤
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
EP3429592A4 (en) * 2016-11-02 2019-10-30 Xiangbei Welman Pharmaceutical Co., Ltd COMPOSITION OF CEFTRIAXONNATRIUM AND SULBACTUMNATRIUM
CN111249284B (zh) * 2016-11-03 2022-10-04 湘北威尔曼制药股份有限公司 治疗淋病奈瑟菌感染的头孢曲松钠舒巴坦钠
RU2665006C1 (ru) * 2017-02-28 2018-08-24 Общество с ограниченной ответственностью "Супербаг Солюшенс" Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
SG11202101255UA (en) 2018-08-09 2021-03-30 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
WO2025165991A1 (en) * 2024-01-31 2025-08-07 The Penn State Research Foundation Biopolymeric anti-antibiotics and methods for making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
DK1468697T3 (da) * 2003-04-14 2008-04-14 Wyeth Corp Sammensætninger indeholdende piperacillin og tazobactam, der er anvendelige til injektion

Also Published As

Publication number Publication date
UA91204C2 (ru) 2010-07-12
RU2397768C2 (ru) 2010-08-27
NZ555075A (en) 2011-02-25
US20130023512A1 (en) 2013-01-24
AU2005310888A1 (en) 2006-06-08
RU2007124325A (ru) 2009-01-10
EP1841432A1 (en) 2007-10-10
US8273732B2 (en) 2012-09-25
WO2006059344B1 (en) 2006-11-02
WO2006059344A1 (en) 2006-06-08
DK1841432T3 (da) 2010-12-06
JP5269415B2 (ja) 2013-08-21
KR101244362B1 (ko) 2013-03-18
ATE476981T1 (de) 2010-08-15
US20100160277A1 (en) 2010-06-24
EP1841432B1 (en) 2010-08-11
BRPI0517128A (pt) 2008-09-30
US9012442B2 (en) 2015-04-21
KR20070067189A (ko) 2007-06-27
ES2349301T3 (es) 2010-12-29
KR20090101514A (ko) 2009-09-28
CY1110886T1 (el) 2015-06-10
JP2008521884A (ja) 2008-06-26
RS51506B (sr) 2011-06-30
HRP20100591T1 (hr) 2010-12-31
PT1841432E (pt) 2010-10-25
PL1841432T3 (pl) 2011-01-31
ZA200704394B (en) 2008-09-25
CN101060846A (zh) 2007-10-24
AU2005310888B2 (en) 2011-01-06
SI1841432T1 (sl) 2011-02-28
MX2007006540A (es) 2008-01-31

Similar Documents

Publication Publication Date Title
ZA200704394B (en) Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
JP2018138578A5 (https=)
TW200806299A (en) Treatment of pain
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
CA2672902A1 (en) Formulations
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
MX2009012093A (es) Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
IL193639A (en) Purified collagen for use as a cellulite treatment drug
NO20071711L (no) Sammensetninger inneholdende piperacillin, tazobactam og en aminokarboksylsyre i et natriumlaktat fortynningsmiddel
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
CN101080221A (zh) 抗药性细菌感染疾病的肠胃外综合治疗
Parikh et al. Preventive analgesia: Effect of small dose of ketamine on morphine requirement after renal surgery
TNSN07419A1 (en) Methods for treating drug resistant cancer
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
SI2576524T1 (en) USE OF METFORMIN IN COMBINATION WITH GLUCOIN-ACTIVE ACTIVATORS, ALSO THE COMPOSITION, COMPARING METFORMIN AND GLUCOIN-ACTIVE ACTUATOR
RU2011113762A (ru) Способы применения композиций с замедленным высвобождением аминопиридина
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
TW200639159A (en) Treatment of pain
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
JP2008540515A (ja) 嚢胞性線維症を含む重症感染症の処置および管理